tldrdailynews.com logo

Gilead's Trodelvy Fails Key Bladder Cancer Trial

1 min read
Source: Endpoints News
Gilead's Trodelvy Fails Key Bladder Cancer Trial
Photo: Endpoints News
TL;DR

Gilead announced that its antibody-drug conjugate Trodelvy failed to meet its primary endpoint in a Phase 3 study for bladder cancer, impacting the company's oncology business.

Topics:businesshealthcare#bladder-cancer#gilead#healthcare#oncology#phase-3-study#trodelvy
Share this article
  1. Gilead's blockbuster ADC Trodelvy fails bladder cancer confirmatory study  Endpoints News
  2. Gilead's Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths  FiercePharma
  3. Gilead Provides Update on Phase 3 TROPiCS-04 Study  Yahoo Finance
  4. Gilead’s Trodelvy Fails to Reach Primary Endpoint in Confirmatory Trial  BioSpace
  5. Gilead's Trodelvy Fails To Show Significant Survival Benefit  Finimize

Want the full story? Read the original reporting

Read on Endpoints News